Sartorius Shows Continued Growth Amid Favorable Conditions

Sartorius AG announced robust growth in its half-year results for 2026, maintaining its positive momentum across both the Bioprocess Solutions and Lab Products & Services divisions. Notably, the Group's operational sales revenue increased by 7.7% in constant currencies, excluding tariff compensation impacts. Furthermore, the underlying EBITDA margin rose to 30.3%, an increase of 0.5 percentage points. Despite uncertainties surrounding U.S. tariff refunds, which influenced non-operational results, Sartorius managed to stabilize sales in the equipment segment, even witnessing slight growth.

Both divisions contributed positively, with Lab Products & Services showing a 5.3% increase in sales revenue, while Bioprocess Solutions grew by 8.3%, excluding tariff compensation effects. Noteworthy was the contribution from MATTEK, acquired in 2025, which added 0.5 percentage points to revenue growth. Amidst these developments, Sartorius confirmed its full-year guidance, projecting further sales revenue growth between 5 to 9% in constant currencies, despite challenges in geopolitical environments and tariff measures.